Schering Corporation

Eric L Gustafson

Wei W Wang

Joseph A Hedrick

Jean E Lachowicz

Suke Wang

Maureen Laverty

Frederick James Monsma, Jr

Elizabeth B Smith

Xiaoxin Yang

The invention relates to the use of the interaction between the GPR78 polypeptide or the GPR26 polypeptide and their identified ligands and antagonists as the basis for screening methods for the identification of agents that modulate the activity of these receptors, and for diagnostic and therapeutic purposes. The agents identified by the screening methods of the invention have use in the treatment of GPR78- and/or GPR26-mediated disorders, including, but not limited to, neurological disorders (such as anxiety disorders), metabolic disorders, cardiovascular disorders, hormone-related disorders, vascular disorders and hyperproliferative disorders (such as cancer).

Modulators of the orphan G protein-coupled receptors GPR78 and GPR26

The present invention provides an isolated mammalian adenosine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by adenosine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian adenosine receptor.

Adenosine receptor

Growing community of inventors

Annandale, NJ, United States of America

Eric L Gustafson